# US 2025/0144075 A1 · Melanin for treating lipofuscin-associated diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144075 A1
- Document ID: US20250144075A1
- Status: Published application
- Kind: A1
- Application number: 18/837,398
- Filed: 2023-02-09
- Published: 2025-05-08
- Earliest claimed: 2022-02-09
- Assignees: Katairo GmbH
- Applicants: Katairo GmbH
- Inventors: Ulrich SCHRAERMEYER
- Web page: https://patentgrep.com/patent/US20250144075A1

## CPC

- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 31/34: having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 27/02: Ophthalmic agents
- A01K 2217/075: inducing loss of function, i.e. knock out
- A01K 2227/105: Murine
- A01K 2267/0306: Animal model for genetic diseases
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to a composition for use in the treatment and/or prophylaxis of a lipofuscin-associated disease, wherein the composition comprises melanin and/or induces melanogenesis.

## Claims

### Claim 1

A composition for use in the treatment of a lipofuscin-associated disease, wherein the composition comprises melanin and/or induces melanogenesis.

### Claim 2 (depends on 1)

The composition for use according to claim 1, wherein melanin interacts with lipofuscin.

### Claim 3 (depends on 1, 2)

The composition for use according to claim 1 or 2, wherein melanin degrades and/or removes lipofuscin.

### Claim 4 (depends on 1, 2, 3)

The composition for use according to any one of claims 1 to 3, wherein thin lamellar membranes (TLMs) are removed.

### Claim 5 (depends on 1, 2, 3, 4)

The composition for use according to any one of claims 1 to 4, wherein the lipofuscin associated disease is a disease of the eye or the CNS.

### Claim 6 (depends on 5)

The composition for use according to claim 5, wherein the lipofuscin associated disease is a disease of the eye and is selected from age-related macular degeneration, Stargardt's disease, Best's disease or Retinitis pigmentosa.

### Claim 7 (depends on 6)

The composition for use according to claim 6, wherein the age-related macular degeneration is dry AMD or wet AMD, preferably dry AMD.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The composition for use according to any one of claims 1 to 7, wherein the treatment comprises administering an injection of the composition to a patient.

### Claim 9

A composition for use in the treatment of a lipofuscin-associated disease, wherein the composition comprises a combination of melanin and/or a melanin inducing agent with a superoxide-generator and/or an NO-generator.

### Claim 10

A composition for use in the treatment of a lipofuscin-associated disease, wherein the composition comprises a combination of melanin and/or a melanin inducing agent with soraprazan and/or ISDN.
